The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
Open accessAbstract
The association of genetic lesions detected by fluorescence in situ hybridization (FISH) with survival was analyzed in 1069 patients with newly presenting myeloma treated in the Medical Research Council Myeloma IX trial, with the aim of identifying patients associated with the worst prognosis. A comprehensive FISH panel was performed, and the lesions associated with short progression-free survival and overall survival (OS) in multivariate analysis were +1q21, del(17p13) and an adverse immunoglobulin heavy chain gene (IGH) translocation group incorporating t(4;14), t(14;16) and t(14;20). These lesions frequently co-segregated, and there was an association between the accumulation of these adverse FISH lesions and a progressive impairment of survival. This observation was used to define a series of risk groups based on number of adverse lesions. Taking this approach, we defined a favorable risk group by the absence of adverse genetic lesions, an intermediate group with one adverse lesion and a high-risk group defined by the co-segregation of >1 adverse lesion. This genetic grouping was independent of the International Staging System (ISS) and so was integrated with the ISS to identify an ultra-high-risk group defined by ISS II or III and >1 adverse lesion. This group constituted 13.8% of patients and was associated with a median OS of 19.4 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Self-citationBortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
The molecular classification of multiple myeloma
Zhan, F., Huang, Y., Colla, S., Stewart, J. P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., et al. (2006) · Blood · doi:10.1182/blood-2005-11-013458 · Cited by 1,133
Shaughnessy, J. D., Zhan, F., Burington, B. E., Huang, Y., Colla, S., Hanamura, I., Stewart, J. P., Kordsmeier, B., Randolph, C., Williams, D. R., et al. (2007) · Blood · doi:10.1182/blood-2006-07-038430 · Cited by 914
Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., et al. (2007) · Blood · doi:10.1182/blood-2006-08-040410 · Cited by 911
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
Fonseca, R., Bergsagel, P. L., Drach, J., Shaughnessy, J., Gutierrez, N., Stewart, A. K., Morgan, G., Van Ness, B., Chesi, M., Minvielle, S., et al. (2009) · Leukemia · doi:10.1038/leu.2009.174 · Cited by 886
Self-citationClinical and biologic implications of recurrent genomic aberrations in myeloma
Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M. M., Kyle, R. A., Dewald, G. W., Van Ness, B., Van Wier, S. A., Henderson, K. J., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3017 · Cited by 660
Morgan, G. J., Davies, F. E., Gregory, W. M., Cocks, K., Bell, S. E., Szubert, A. J., Navarro-Coy, N., Drayson, M. T., Owen, R. G., Feyler, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62051-x · Cited by 575
Self-citationHanamura, I., Stewart, J. P., Huang, Y., Zhan, F., Santra, M., Sawyer, J. R., Hollmig, K., Zangarri, M., Pineda-Roman, M., van Rhee, F., et al. (2006) · Blood · doi:10.1182/blood-2006-03-009910 · Cited by 479
Avet-Loiseau, H., Leleu, X., Roussel, M., Moreau, P., Guerin-Charbonnel, C., Caillot, D., Marit, G., Benboubker, L., Voillat, L., Mathiot, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3945 · Cited by 424
Tricot, G., Barlogie, B., Jagannath, S., Bracy, D., Mattox, S., Vesole, D., Naucke, S., & Sawyer, Jr. (1995) · Blood · doi:10.1182/blood.v86.11.4250.bloodjournal86114250 · Cited by 395
Keats, J. J., Reiman, T., Maxwell, C. A., Taylor, B. J., Larratt, L. M., Mant, M. J., Belch, A. R., & Pilarski, L. M. (2003) · Blood · doi:10.1182/blood-2002-06-1675 · Cited by 382
Decaux, O., Lodé, L., Magrangeas, F., Charbonnel, C., Gouraud, W., Jézéquel, P., Attal, M., Harousseau, J.-L., Moreau, P., Bataille, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8545 · Cited by 371
Gertz, M. A. (2005) · Blood · doi:10.1182/blood-2005-04-1411 · Cited by 360
Drach, J., Ackermann, J., Fritz, E., Krömer, E., Schuster, R., Gisslinger, H., DeSantis, M., Zojer, N., Fiegl, M., Roka, S., et al. (1998) · Blood · doi:10.1182/blood.v92.3.802 · Cited by 325
Zojer, N., Königsberg, R., Ackermann, J., Fritz, E., Dallinger, S., Krömer, E., Kaufmann, H., Riedl, L., Gisslinger, H., Schreiber, S., et al. (2000) · Blood · doi:10.1182/blood.v95.6.1925 · Cited by 321
Fonseca, R., Van Wier, S. A., Chng, W. J., Ketterling, R., Lacy, M. Q., Dispenzieri, A., Bergsagel, P. L., Rajkumar, S. V., Greipp, P. R., Litzow, M. R., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404403 · Cited by 213
Nair, B., van Rhee, F., Shaughnessy, J. D., Anaissie, E., Szymonifka, J., Hoering, A., Alsayed, Y., Waheed, S., Crowley, J., & Barlogie, B. (2010) · Blood · doi:10.1182/blood-2009-11-255620 · Cited by 201
Chang, H., Qi, C., Yi, Q.-L., Reece, D., & Stewart, A. K. (2005) · Blood · doi:10.1182/blood-2004-04-1363 · Cited by 201
Chang, H., Sloan, S., Li, D., Zhuang, L., Yi, Q., Chen, C. I., Reece, D., Chun, K., & Keith Stewart, A. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04867.x · Cited by 193
Gutiérrez, N. C., Castellanos, M. V., Martín, M. L., Mateos, M. V., Hernández, J. M., Fernández, M., Carrera, D., Rosiñol, L., Ribera, J. M., Ojanguren, J. M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404413 · Cited by 185
Self-citationNeben, K., Jauch, A., Bertsch, U., Heiss, C., Hielscher, T., Seckinger, A., Mors, T., Muller, N. Z., Hillengass, J., Raab, M. S., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.016436 · Cited by 173
Pérez-Simón, J. A., Garcı́a-Sanz, R., Tabernero, M. D., Almeida, J., González, M., Fernández-Calvo, J., Moro, M. J., Hernández, J. M., Miguel, J. F. S., & Orfão, A. (1998) · Blood · doi:10.1182/blood.v91.9.3366 · Cited by 169
Pineda‐Roman, M., Zangari, M., Haessler, J., Anaissie, E., Tricot, G., Van Rhee, F., Crowley, J., Shaughnessy, J. D., & Barlogie, B. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06921.x · Cited by 166
Harousseau, J.-L., Avet-Loiseau, H., Attal, M., Charbonnel, C., Garban, F., Hulin, C., Michallet, M., Facon, T., Garderet, L., Marit, G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1060 · Cited by 164
Chiecchio, L., Protheroe, R. K. M., Ibrahim, A. H., Cheung, K. L., Rudduck, C., Dagrada, G. P., Cabanas, E. D., Parker, T., Nightingale, M., Wechalekar, A., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404304 · Cited by 161
Self-citationTranslocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
Avet‐Loiseau, H., Malard, F., Campion, L., Magrangeas, F., Sebban, C., Lioure, B., Decaux, O., Lamy, T., Legros, L., Fuzibet, J., et al. (2010) · Blood · doi:10.1182/blood-2010-07-295105 · Cited by 130
Dickens, N. J., Walker, B. A., Leone, P., Johnson, D. C., Brito, J. L. R., Zeisig, A., Jenner, M. W., Boyd, K. D., Gonzalez, D., Gregory, W. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2831 · Cited by 130
Self-citationRoss, F. M., Chiecchio, L., Dagrada, G. P., Protheroe, R. K. M., Stockley, D. M., Harrison, C. J., Cross, N. C. P., Szubert, A. J., Drayson, M. T., Morgan, G. J., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.016329 · Cited by 101
Self-citationAge has a profound effect on the incidence and significance of chromosome abnormalities in myeloma
Ross, F. M., Ibrahim, A., Vilain-Holmes, A., Winfield, M., Chiecchio, L., Protheroe, R. K. M., Strike, P. W., Gunasekera, J. L., Jones, A. V., Harrison, C. J., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403857 · Cited by 81
Self-citation
Cited by
Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210
Self-citationKumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,177
Sonneveld, P., Avet-Loiseau, H., Lonial, S., Usmani, S., Siegel, D., Anderson, K. C., Chng, W.-J., Moreau, P., Attal, M., Kyle, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-01-631200 · Cited by 928
The genetic architecture of multiple myeloma
Morgan, G. J., Walker, B. A., & Davies, F. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3257 · Cited by 913
Self-citationvan de Donk, N. W. C. J., Pawlyn, C., & Yong, K. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 869
Metadata
- Authors
- Boyd, K. D., Ross, F. M., Chiecchio, L., Dagrada, G. P., Konn, Z. J., Tapper, W. J., Walker, B. A., Wardell, C. P., Gregory, W. M., Szubert, A. J., Bell, S. E., Child, J. A., Jackson, G. H., Davies, F. E., Morgan, G. J., & on behalf of the NCRI Haematology Oncology Studies Group
- Venue
- Leukemia
- Published
- 2011-08-12
- Volume
- 26
- Issue
- 2
- Pages
- 349-355
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2046408556
- Cited by
- 340
- References
- 30
- FWCI
- 11.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.